PPT-Ledipasvir-Sofosbuvir +/- 3

rd DAA in HCV Genotype 1 NIAID SYNERGY Genotype 1 Phase 2 Treatment Naïve unfavorable baseline treatment characteristics Kohli A et al Lancet 2015385110713 Source. + Ribavirin to Prevent Post-Transplant HCV Recurrence . Phase 2. Curry . MP, et al. Gastroenterology. 2014;September 24. [. Epub. ahead of print] . Treatment. Naïve and Treatment . Experienced. Liver Transplantation. + Sofosbuvir in HCV GT 1-4 and HIV Coinfection. ALLY-2 Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Wyles DL, . et al. . N Engl J Med. 2015;373:714-25.. Source: Wyles DL, et al. N Engl J Med. 2015;373:714-25.. Matthew Luu, Yuan Fang (Pearl) Cai, Shiming Sun, . Ziyi Cheng. PHM142 Fall . 2016. Coordinator. : Dr. Jeffrey Henderson. Instructor: Dr. David Hampson. What is Hepatitis C? . Flaviviridae. virus family. ION-4. Phase . 3. Treatment. Naïve and Treatment . Experienced. Naggie. S, . et al. . N . Engl. J Med 2015;378:705-13.. HIV Coinfection. Source: . Naggie. S, et al. N . Engl. J Med 2015;378:705-13.. HIV Coinfection & HCV . GT 1,2,3. PHOTON-1 Trial. Phase . 3. Sulkowski. MS, et al. JAMA. 2014;312:353-61.. Treatment. Naïve and Treatment . Experienced. HIV Coinfection. Source: . Sulkowski. MS, et al. JAMA. 2014;312:353-61.. Harvoni. ). Prepared by: . David H. Spach, MD and H. Nina Kim, MD MSc. Last . Updated: . December 15, 2015. Background and Dosing. Ledipasvir-Sofosbuvir (. Harvoni. ). Ledipasvir-Sofosbuvir (. Harvoni. VALENCE Trial. Phase . 3. Treatment. Naïve and Treatment . Experienced. Zeuzem. S, et al. . N . Engl. J Med. 2014;370:1993-2001. Source: . Zeuzem. S, et al. N . Engl. J Med. 2014;370:1993-. 2001.. . or 3 . LONESTAR-2. Phase 2. Treatment. . Experienced. Lawitz. . E, et al. . Hepatology. . 2015:61:769-75.. Source: . Lawitz. E, et al. . Hepatology. . . 2015:61:769-75.. Sofosbuvir + . PEG + RBV . in DAA. -Naïve GT . 1-6 . POLARIS-2. Phase 3. . Treatment Naïve and . Treament. Experienced (DAA Naïve) . Jacobson IM, . et al. . Gastroenterology. 2017;153:113-22.. Source: Jacobson IM, et al. Gastroenterology. 2017;153:113-22.. in Genotype 3. ASTRAL-3. Phase 3. . Treatment. . Naïve & Experienced. Foster GR, . et al. . N . Engl. J Med. . 2015. ;373:2608-17.. *Published in tandem with ASTRAL-2 Trial. Source: Foster GR, . SOLAR-1 (Cohorts A and B). Phase . 2 . Treatment Naïve and Treatment Experienced. Charlton M, al. Gastroenterology. 2015; 149:649-59.. Source: Charlton M, . et al. . Gastroenterology. 2015; 149:649-59.. Sofosbuvir + Ribavirin to Prevent Post-Transplant HCV Recurrence Phase 2 Curry MP, et al. Gastroenterology . 2015;148:100-7. Treatment Naïve and Treatment Experienced Liver Transplantation Source: Curry MP, et . with Advanced Liver Disease. ALLY-3+ Study. Phase 3. . Treatment. -. Naïve . and . Treatment-Experienced. Leroy V, . et al. . Hepatology 2016;63:1430-41.. Source: Leroy V, et al. Hepatology . 2016;63:1430-41.. Following Liver Transplantation. Phase 2. Charlton M, . et al. . Gastroenterology. 2015;148:108-17.. Treatment. Naïve and Treatment . Experienced. Liver Transplantation. Source: Charlton M, et al. Gastroenterology. 2015;148:108-17..